701510login-checkAdolescent, young adult survivors of kidney cancer at high risk for cardiovascular disease |
By Jennifer Southall
Adolescent and young adult survivors of kidney cancer appeared at significantly increased risk for left ventricular ejection fraction, according to study results published in Journal of the National Comprehensive Cancer Network.
Nearly half of adolescents and young adults (AYAs) treated with sorafenib (Nexavar, Bayer) and one-third of those treated with sunitinib (Sutent, Pfizer) developed hypertension, researchers noted.
Read the full article in Healio.
701510login-checkAdolescent, young adult survivors of kidney cancer at high risk for cardiovascular disease |